Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2019

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

	Three Months Ended				Six Months Ended
(In thousands)	December 31,				December 31,
Medical Indication	2019		2018		2019		2018
Analgesic	$	2,111	$	2,547	$	3,995	$	4,376
Anti-Psychosis		22,697		14,036		50,730		24,925
Cardiovascular		23,972		25,680		45,579		47,450
Central Nervous System		19,331		7,373		38,588		21,659
Endocrinology		—		88,477		—		142,355
Gastrointestinal		18,313		12,943		35,275		30,537
Infectious Disease		18,078		4,616		29,973		9,096
Migraine		10,878		12,551		20,021		22,288
Respiratory/Allergy/Cough/Cold		3,075		3,388		5,781		6,972
Urinary		1,233		1,596		1,668		3,137
Other		9,934		12,606		19,796		23,411
Contract manufacturing revenue		6,488		7,905		12,046		12,566
Total net sales	$	136,110	$	193,718	$	263,452	$	348,772

Summary of products which accounted for at least 10% of total net sales

	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2019		2018		2019		2018
Product 1	15	%	7	%	18	%	7	%
Product 2	10	%	—	%	9	%	—	%
Product 3	—	%	46	%	—	%	41	%

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2019		2018		2019		2018
Customer A	26	%	14	%	26	%	16	%
Customer B	21	%	18	%	23	%	23	%
Customer C	8	%	13	%	10	%	11	%
Customer D	—	%	14	%	—	%	8	%